Latest News

Berkshire Hathaway's stock has rebounded as investors increasingly worry about the market.

Management raised full-year free cash flow guidance after Algoma Steel settlement.

Membership growth surged 65% as company invests heavily in club expansion.

Before moving forward, make certain a Roth conversion actually makes sense.

The stocks listed here all have excellent fundamentals and are trading within 10% of their 52-week lows.

Apple shares near record highs on strong iPhone Duo foldable demand, but a Loop Capital downgrade and nearly 40 times earnings valuation raise questions ahead of its Nov. 2 earnings report.

International strength is carrying the company for now, but investors should ask how long that can last.

Fort Lauderdale hub expansion and premium products drive margin growth.

Record $2.5 trillion AUM and 40.7% margins drive strong Q3 results.

Data center orders surged 200% as utility spending caution pressured near-term revenue.

Paint maker navigates soft demand while pursuing $75M cost savings in 2027.

EV sales plunged 76% as revenue declined 8%, but management eyes SG&A efficiency gains ahead.

Pool inventory reset complete; Taco acquisition closed, positioning for 2027 growth.

Revenue hit $4.4 billion with 8% growth; net new bookings surged 15% year over year.

Volume growth hit 22 consecutive quarters, but payer mix shifts cost $400M in EBITDA.

The case for ISCV is lower fees and broader diversification. The case for SLYV is that it only owns companies that are actually making money.

Profit growth is outpacing revenue gains, giving the company firepower to advance pipeline candidates without diluting shareholders.

The chipmaker and social media titan are deepening their partnership.

Kroger's stores see steady demand, no matter the economic climate.

Polaris raised its 2026 guidance for the second time this year.

Community Financial System (NYSE:CBU) reported record operating results for the third quarter of 2026, with operating diluted earnings per share rising 16.5% from a year earlier and 9.5% from the prior quarter, President and Chief Executive Officer Dimitar Karaivanov said during the company’s earnin

GSK (NYSE:GSK) highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC mo-rez, PD-1 therapy dostarlimab and ROS1 inhibitor JIDEYTRO. Hesham Abdullah, GSK’s senior vice pre

Brown & Brown (NYSE:BRO) reported third-quarter revenue of $1.7 billion, up 7.4% from a year earlier, as improvement in its retail business helped offset pressure in specialty distribution operations. Organic revenue rose 1.2%, or 1.5% including organic contingent commissions. Adjusted EBITDAC

Brixmor Property Group (NYSE:BRX) reported higher third-quarter funds from operations and same-property net operating income, supported by leasing activity, occupancy gains and rent increases across its grocery-anchored retail portfolio. The company also raised its full-year outlook for same-propert

Banco Latinoamericano de Comercio Exterior (NYSE:BLX), known as Bladex, reported record commercial portfolio and net interest income levels in the third quarter of 2026, supported by loan growth, expanding deposits and a $1 billion one-year sovereign transaction with Panama. Net income totaled $63.